ATE344249T1 - Pyrazinone, diese verbindungen enthaltende zusammenstellungen - Google Patents

Pyrazinone, diese verbindungen enthaltende zusammenstellungen

Info

Publication number
ATE344249T1
ATE344249T1 AT00947711T AT00947711T ATE344249T1 AT E344249 T1 ATE344249 T1 AT E344249T1 AT 00947711 T AT00947711 T AT 00947711T AT 00947711 T AT00947711 T AT 00947711T AT E344249 T1 ATE344249 T1 AT E344249T1
Authority
AT
Austria
Prior art keywords
compounds
pyrazinones
compositions containing
caspase
hydrates
Prior art date
Application number
AT00947711T
Other languages
German (de)
English (en)
Inventor
Yongxin Han
Andre Giroux
Robert Zamboni
Daniel J Mckay
Christopher I Bayly
Erich L Grimm
John Colucci
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Application granted granted Critical
Publication of ATE344249T1 publication Critical patent/ATE344249T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
AT00947711T 1999-07-19 2000-07-17 Pyrazinone, diese verbindungen enthaltende zusammenstellungen ATE344249T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14446699P 1999-07-19 1999-07-19
US17061499P 1999-12-14 1999-12-14

Publications (1)

Publication Number Publication Date
ATE344249T1 true ATE344249T1 (de) 2006-11-15

Family

ID=26842025

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00947711T ATE344249T1 (de) 1999-07-19 2000-07-17 Pyrazinone, diese verbindungen enthaltende zusammenstellungen

Country Status (9)

Country Link
US (2) US6444811B1 (enExample)
EP (1) EP1202976B1 (enExample)
JP (1) JP4749640B2 (enExample)
AT (1) ATE344249T1 (enExample)
AU (1) AU773317B2 (enExample)
CA (1) CA2378834C (enExample)
DE (1) DE60031686T2 (enExample)
ES (1) ES2274795T3 (enExample)
WO (1) WO2001005772A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1202976B1 (en) * 1999-07-19 2006-11-02 Merck Frosst Canada Ltd. Pyrazinones, compositions containing such compounds
US20020155172A1 (en) * 2000-04-07 2002-10-24 Junying Yuan Methods and compounds for decreasing cell toxicity or death
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
AU2002246065A1 (en) * 2001-01-26 2002-08-06 Evotec Oai Ag Methods and means for detecting enzymatic cleavage and linkage reactions
FR2827288B1 (fr) * 2001-07-12 2003-10-31 Servier Lab Nouveaux derives d'octahydro-2h-pyrido[1,2-a]pyrazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2003211052A1 (en) 2002-02-11 2003-09-04 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
US7960398B2 (en) 2002-04-19 2011-06-14 Vertex Pharmaceuticals Incorporated Regulation of TNF-alpha
GB2417360B (en) 2003-05-20 2007-03-28 Kagutech Ltd Digital backplane
HUE024556T2 (hu) 2004-03-12 2016-02-29 Vertex Pharma Eljárások és intermedierek aszparagin acetál kapszáz inhibitorok elõállítására
CA2567080A1 (en) 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
US7879891B2 (en) 2005-07-28 2011-02-01 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
KR20080042286A (ko) * 2006-11-09 2008-05-15 주식회사 엘지생명과학 피리다지논 구조를 포함하는 캐스파제 저해제
WO2009019115A1 (en) 2007-08-03 2009-02-12 Sanofi-Aventis Caspase imaging probes
WO2009103432A2 (en) * 2008-02-21 2009-08-27 Sanofi-Aventis Covalently binding imaging probes
US9116157B2 (en) 2010-11-05 2015-08-25 Brandeis University Ice-cleaved alpha-synuclein as a biomarker
CN109180690A (zh) * 2018-10-15 2019-01-11 烟台显华化工科技有限公司 一类用作蓝色荧光材料的氮杂芳香化合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
WO1999011267A1 (en) 1997-09-05 1999-03-11 Merck & Co., Inc. Pyrazinone thrombin inhibitors
NZ331993A (en) * 1996-04-23 2000-04-28 Merck & Co Inc Pyrazinone thrombin inhibitors
EP0934305A4 (en) 1996-08-29 2001-04-11 Merck & Co Inc INTEGRINANTAGONISTS
US5981546A (en) * 1996-08-29 1999-11-09 Merck & Co., Inc. Integrin antagonists
JP4199309B2 (ja) * 1996-09-06 2008-12-17 日本化薬株式会社 新規アセトアミド誘導体およびプロテアーゼ阻害
AU728006B2 (en) 1997-03-24 2001-01-04 Merck & Co., Inc. Thrombin inhibitors
US5866573A (en) 1997-04-21 1999-02-02 Merck & Co., Inc. Pyrazinone thrombin inhibitors
EP1202976B1 (en) * 1999-07-19 2006-11-02 Merck Frosst Canada Ltd. Pyrazinones, compositions containing such compounds

Also Published As

Publication number Publication date
CA2378834A1 (en) 2001-01-25
DE60031686T2 (de) 2007-08-30
AU773317B2 (en) 2004-05-20
EP1202976A1 (en) 2002-05-08
AU6143200A (en) 2001-02-05
EP1202976B1 (en) 2006-11-02
JP2003505378A (ja) 2003-02-12
US6444811B1 (en) 2002-09-03
US20030236402A1 (en) 2003-12-25
CA2378834C (en) 2009-07-07
DE60031686D1 (de) 2006-12-14
WO2001005772A1 (en) 2001-01-25
JP4749640B2 (ja) 2011-08-17
US6699856B2 (en) 2004-03-02
ES2274795T3 (es) 2007-06-01

Similar Documents

Publication Publication Date Title
ATE344249T1 (de) Pyrazinone, diese verbindungen enthaltende zusammenstellungen
JO2282B1 (en) Oxazole derivatives
MX2007000028A (es) Derivados de nicotinamida y su uso como agentes terapeuticos.
ECSP066314A (es) Derivados piridilo y su uso como agentes terapéuticos
AP1860A (en) Aryl fused azapolycyclic compounds.
GB0413087D0 (en) Therapeutic compounds
WO2001064639A3 (en) Pde iv inhibiting amides, compositions and pharmaceutical use
AU2003301020A1 (en) Isoquinolinone derivatives and their use as therapeutic agents
EA201000643A1 (ru) Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе
ATE407928T1 (de) Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
WO2004033455A3 (en) Hemisuccinate salts of heterocyclic dpp-iv inhibitors
WO2005011657A3 (en) Piperazine derivatives and their use as therapeutic agents
ATE245152T1 (de) Dioxocyclopentylhydroxamsäure
ATE264852T1 (de) Chinolinderivate als antibakterielle mittel
MX2007003321A (es) Derivados heterociclicos y su uso como agentes terapeuticos.
MXPA05014082A (es) Acidos biariloximetilarenocarboxilicos.
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
WO2007046868A3 (en) Thiazolidine derivatives and their uses as therapeutic agents
WO2007046867A3 (en) Piperidine derivatives and their uses as therapeutic agents
SE9902267D0 (sv) New compounds
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents
DE60107832D1 (en) Chromenylmethylpyrimidindiamine als antibakterielle wirkstoffe
TW200732304A (en) Piperidine derivatives
DE60119514D1 (de) Amidderivate der 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentansäure

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties